Activity of bortezomib in adult de novo and relapsed acute myeloid leukemia.
Lidia Gil(Poznan University of Medical Sciences), Mariusz Wysocki(Medical University of Lublin), Robert Dębski(Nicolaus Copernicus University), Mieczysław Komarnicki(Poznan University of Medical Sciences), Beata Rafińska, Jan Styczyński(Nicolaus Copernicus University), Maciej Kaźmierczak(Silesian University of Technology), Adam Nowicki, Dominik Dytfeld, Beata Kołodziej, Małgorzata Kubicka
PubMed
February 12, 2008
Cited by 27
Related Papers
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
|The Lancet Oncology|2019|493
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
|The Lancet Oncology|2021|266